OncoMatch/Clinical Trials/NCT06357598
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
Is NCT06357598 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Tislelizumab and Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC) for non-small-cell lung cancer (nsclc).
Treatment: Tislelizumab · Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC) · Carboplatin or Cisplatin — Explorative study, which evaluates the effect of Tislelizumab combined with chemotherapy in neoadjuvant treatment of stage Ⅲ unresectable non-small-cell lung carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Disease stage
Required: Stage IIIA, IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
without radiotherapy, chemotherapy, surgery or molecule-targeted treatment
Cannot have received: chemotherapy
without radiotherapy, chemotherapy, surgery or molecule-targeted treatment
Cannot have received: surgery
without radiotherapy, chemotherapy, surgery or molecule-targeted treatment
Cannot have received: targeted therapy
without radiotherapy, chemotherapy, surgery or molecule-targeted treatment
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Patients has received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulator or synergistically inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137)
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L; PLT ≥ 100×10^9/L; HB ≥ 90 g/L
Kidney function
sCr ≤ 1.5×ULN; endogenous creatinine clearance rate ≥ 45 ml/min (Cockcroft-Gault formula)
Liver function
TBIL ≤ 1.5×ULN; ALT, AST ≤ 2.5×ULN
The main organ function meets the following criteria:1) Blood routine:a. ANC ≥ 1.5×109/L; b. PLT ≥ 100×109/L; c. HB ≥ 90 g/L; 2) Blood biochemistry:TBIL ≤ 1.5×ULN;ALT、AST≤ 2.5×ULN;sCr≤1.5×ULN; 3) Blood coagulation: INR≤1.5×ULN and APTT≤1.5×ULN，endogenous creatinine clearance rate≥45ml/min(Cockcroft-Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify